Download - Harnessing Nano for Drug Delivery
![Page 1: Harnessing Nano for Drug Delivery](https://reader033.vdocuments.site/reader033/viewer/2022042320/625d0e9ccb889378fe23acc4/html5/thumbnails/1.jpg)
1 of 32
Harnessing Nano for Drug Delivery
Kayte Fischer
3/17/15
![Page 2: Harnessing Nano for Drug Delivery](https://reader033.vdocuments.site/reader033/viewer/2022042320/625d0e9ccb889378fe23acc4/html5/thumbnails/2.jpg)
2 of 32
What is Drug Delivery?
![Page 3: Harnessing Nano for Drug Delivery](https://reader033.vdocuments.site/reader033/viewer/2022042320/625d0e9ccb889378fe23acc4/html5/thumbnails/3.jpg)
3 of 32
What is Drug Delivery?
![Page 4: Harnessing Nano for Drug Delivery](https://reader033.vdocuments.site/reader033/viewer/2022042320/625d0e9ccb889378fe23acc4/html5/thumbnails/4.jpg)
4 of 32
Why is drug delivery useful?
Patient friendly
•Easy to use
•Reduced pain
•Reduced frequency
Improved adherence
Improved pharmaco-
kinetics
Improved Patient
Outcomes
![Page 5: Harnessing Nano for Drug Delivery](https://reader033.vdocuments.site/reader033/viewer/2022042320/625d0e9ccb889378fe23acc4/html5/thumbnails/5.jpg)
5 of 32
Opportunities Incorporating Existing Drugs
VALUE
TIME, CAPITAL,
RISK
Generic Drug
New Drug 10-15 years, $1-2B
41% Phase 3 Success Rate*
Drug Delivery Product 3-6 years, $10-50M
66% Phase 3 Success Rate*
*Data for comparable products presented by Teva Pharmaceuticals at PODD conference 2014
![Page 6: Harnessing Nano for Drug Delivery](https://reader033.vdocuments.site/reader033/viewer/2022042320/625d0e9ccb889378fe23acc4/html5/thumbnails/6.jpg)
6 of 32
Different Systems, Different Hurdles
• Mucosal (Oral, gastrointestinal, buccal, ocular, vaginal, alveolar, bronchial)
– Thick coating of slow-flowing mucus – Often active immune response
• Dermal – Thick and hydrophobic – Exposed externally
• Parenteral (Intravenous, intramuscular, subcutaneous, cranial)
– Needles/invasive
• General – Bioavailability (eg: hepatic first pass clearance)
![Page 7: Harnessing Nano for Drug Delivery](https://reader033.vdocuments.site/reader033/viewer/2022042320/625d0e9ccb889378fe23acc4/html5/thumbnails/7.jpg)
7 of 32
What’s going on in the body at the nano level?
• Transportation • Internalization
(eg: vesicles) • Migration (eg:
cilia) • Reorganization
(eg: microvilli)
• Actuation • DNA replication
• Communication • Receptor binding
![Page 8: Harnessing Nano for Drug Delivery](https://reader033.vdocuments.site/reader033/viewer/2022042320/625d0e9ccb889378fe23acc4/html5/thumbnails/8.jpg)
8 of 32
Why Micro/Nano?
• Unique properties – Surface area to volume ratio – Integration with electronics – Scalable manufacturing via
semiconductor techniques – Novel material properties (color,
electrical properties, etc)
• Biological scale – Cell membrane interactions – Cell signaling interactions – Close in size to macromolecules
Dong-Joo Kim et al 2012 Nanotechnology 23
![Page 9: Harnessing Nano for Drug Delivery](https://reader033.vdocuments.site/reader033/viewer/2022042320/625d0e9ccb889378fe23acc4/html5/thumbnails/9.jpg)
9 of 32
Opportunities for Nano-Enabled Drug Delivery
Free floating
• Nanoparticles
Coatings/integral
• Nanowires
• Nanopores/Nanotubes
Popat, et al. Biomaterials 28 (2007).
http://phys.org/news104677694.html
![Page 10: Harnessing Nano for Drug Delivery](https://reader033.vdocuments.site/reader033/viewer/2022042320/625d0e9ccb889378fe23acc4/html5/thumbnails/10.jpg)
10 of 32 Microvilli on Cells
Nanowire-coated Devices
Cell-Nanowire Interface
10
20 microns
Nanowires and microvilli are similar in scale
Fischer, Kathleen (2010) Doctoral Dissertation. Silicon Nanowires for Bioadhesion and Drug Delivery.
![Page 11: Harnessing Nano for Drug Delivery](https://reader033.vdocuments.site/reader033/viewer/2022042320/625d0e9ccb889378fe23acc4/html5/thumbnails/11.jpg)
11 of 32
5 µm
Cell-Nanowire Interface
Nanoscale features allow interdigitation with microvilli, leading to increased van der Waals force
500 nm
1 µm
Fischer, Kathleen (2010) Doctoral Dissertation. Silicon Nanowires for Bioadhesion and Drug Delivery.
![Page 12: Harnessing Nano for Drug Delivery](https://reader033.vdocuments.site/reader033/viewer/2022042320/625d0e9ccb889378fe23acc4/html5/thumbnails/12.jpg)
12 of 32
Nanocoatings
Kam, et al. Nano Letters, 2013. https://pharm.ucsf.edu/desai/research/vascular-stents
![Page 13: Harnessing Nano for Drug Delivery](https://reader033.vdocuments.site/reader033/viewer/2022042320/625d0e9ccb889378fe23acc4/html5/thumbnails/13.jpg)
13 of 32
Diffusion from Nanoporous Silicon Membranes
Fine et al., Lab on a Chip, 2010
Martin et al., 2005, Journal of Controlled Release
Lopez et al., 2006, Biomaterials
![Page 14: Harnessing Nano for Drug Delivery](https://reader033.vdocuments.site/reader033/viewer/2022042320/625d0e9ccb889378fe23acc4/html5/thumbnails/14.jpg)
14 of 32
Inorganic Nanoporous Devices
Titania nanotubular membranes
Silicon nanochannels
Alumina nanoporous capsules
Scale bar – 500 nm
![Page 15: Harnessing Nano for Drug Delivery](https://reader033.vdocuments.site/reader033/viewer/2022042320/625d0e9ccb889378fe23acc4/html5/thumbnails/15.jpg)
15 of 32
Nano Precision Medical www.nanoprecisionmedical.com
![Page 16: Harnessing Nano for Drug Delivery](https://reader033.vdocuments.site/reader033/viewer/2022042320/625d0e9ccb889378fe23acc4/html5/thumbnails/16.jpg)
16 of 32
Management Team
Adam Mendelsohn, PhD Chief Executive Officer Director
Kayte Fischer, PhD Chief Technology Officer
Lily Peng, MD, PhD Consulting VP of Clinical Development
Original Founding Team Non-Founding Management
Adam Monkowski, PhD VP of Device Technology Development
Tomoyuki Yoshie, PhD VP of Device Research
Wouter Roorda, PhD VP of Pharmaceutical Product Development
![Page 17: Harnessing Nano for Drug Delivery](https://reader033.vdocuments.site/reader033/viewer/2022042320/625d0e9ccb889378fe23acc4/html5/thumbnails/17.jpg)
17 of 32
Benefits of NanoPortal Device
Constant Rate Delivery
No New Materials Adherence Assured
Large Payload in a Small Device
![Page 18: Harnessing Nano for Drug Delivery](https://reader033.vdocuments.site/reader033/viewer/2022042320/625d0e9ccb889378fe23acc4/html5/thumbnails/18.jpg)
18 of 32
NanoPortalTM Membrane
![Page 19: Harnessing Nano for Drug Delivery](https://reader033.vdocuments.site/reader033/viewer/2022042320/625d0e9ccb889378fe23acc4/html5/thumbnails/19.jpg)
19 of 32
Tube bottoms, as fabricated Diameters can be modified
Side view ~60 microns
Most lengths can be achieved
Nanotube tops Diameters can be modified
As-Fabricated Titania Nanotubes
1 µm
![Page 20: Harnessing Nano for Drug Delivery](https://reader033.vdocuments.site/reader033/viewer/2022042320/625d0e9ccb889378fe23acc4/html5/thumbnails/20.jpg)
20 of 32
Nanoscale Constrained Release
Time
Mas
s re
leas
ed
Fickian
Non-Fickian
Dru
g R
ele
ase
d
Time
Fickian, diminishing release-rate over time
Non-Fickian, constant release-rate over time
Drug release curves over time
NanoPortalTM Technology
![Page 21: Harnessing Nano for Drug Delivery](https://reader033.vdocuments.site/reader033/viewer/2022042320/625d0e9ccb889378fe23acc4/html5/thumbnails/21.jpg)
21 of 32
Polyethylene glycol, 40 kDa, Fickian release
NanoPortalTM Exhibits Size-Dependent Constant-Rate Delivery
(data produced from prior-generation membranes)
0.00%
20.00%
40.00%
60.00%
80.00%
0
0.2
0.4
0.6
0.8
1
1.2
1.4
0 5 10 15 20 25 30
% o
f lo
ade
d m
ass
elu
ted
Tota
l mas
s e
lute
d (
mg)
Time (days)
b)
0.00%
10.00%
20.00%
30.00%
40.00%
50.00%
60.00%
70.00%
80.00%
0
10
20
30
40
50
60
70
80
0 50 100
% o
f lo
ade
d m
ass
elu
ted
Tota
l mas
s e
lute
d (
ug)
Time (days)
FITC-Fab2, 110 kDa, Constant-rate release
Similar membranes used for both molecules
![Page 22: Harnessing Nano for Drug Delivery](https://reader033.vdocuments.site/reader033/viewer/2022042320/625d0e9ccb889378fe23acc4/html5/thumbnails/22.jpg)
22 of 32
Controllable Nanotube Diameters
Decreasing nanotube diameter
0 nm pore size 17 nm pore size 33 nm pore size
Scale bars are 200 nm
![Page 23: Harnessing Nano for Drug Delivery](https://reader033.vdocuments.site/reader033/viewer/2022042320/625d0e9ccb889378fe23acc4/html5/thumbnails/23.jpg)
23 of 32
0.00%
20.00%
40.00%
60.00%
80.00%
100.00%
0
0.5
1
1.5
2
0 5 10 15 20 25 30
% o
f lo
ade
d m
ass
elu
ted
In V
itro
Ru
nn
ing
tota
l mas
s
(mg
PEG
MW
=40
kD
a)
Devices Function in Rats
Delivery Complete at Day 14 Identical devices tested in parallel in vitro (top) and in vivo (bottom); n=5
Delivery is complete around 80-85% of loaded mass
Decays as expected after delivery is complete 0
100
200
300
400
500
600
0 5 10 15 20 25 30
In V
ivo
Pla
sma
con
cen
trat
ion
(n
g/m
l PEG
MW
=40
kD
a)
Time (days)
![Page 24: Harnessing Nano for Drug Delivery](https://reader033.vdocuments.site/reader033/viewer/2022042320/625d0e9ccb889378fe23acc4/html5/thumbnails/24.jpg)
24 of 32
NanoPortalTM as a Platform Technology
![Page 25: Harnessing Nano for Drug Delivery](https://reader033.vdocuments.site/reader033/viewer/2022042320/625d0e9ccb889378fe23acc4/html5/thumbnails/25.jpg)
25 of 32
Classes of Ideal Drug Candidates
Molecule Type Example Indication
Small Molecules with Compliance Issues
Anti-psychotics (Risperidone)
Schizophrenia, Bipolar Disorder
Small Peptides / Hormones GLP-1 Agonist (Exenatide) Diabetes
Enzyme Replacements Glucocerebrosidase
(Cerezyme) Gaucher, Fabry
Antibodies Natalizumab
(Tysabri) Multiple Sclerosis
siRNA Miravirsen HCV
Selection Criteria 1. Chronic treatments 2. Constant-rate delivery is desirable
Top Pipeline Opportunities:
Exenatide, Teduglutide, Octreotide
![Page 26: Harnessing Nano for Drug Delivery](https://reader033.vdocuments.site/reader033/viewer/2022042320/625d0e9ccb889378fe23acc4/html5/thumbnails/26.jpg)
26 of 32
The Original Idea and Team
![Page 27: Harnessing Nano for Drug Delivery](https://reader033.vdocuments.site/reader033/viewer/2022042320/625d0e9ccb889378fe23acc4/html5/thumbnails/27.jpg)
27 of 32
Getting Started (2007-2010)
• Business plan competitions – 2007-2009
• Grant funding – 2009
• Incorporation – 2009
• IP negotiations – 2010 3 Co-founders
2 Co-founders + 1 Employee
![Page 28: Harnessing Nano for Drug Delivery](https://reader033.vdocuments.site/reader033/viewer/2022042320/625d0e9ccb889378fe23acc4/html5/thumbnails/28.jpg)
28 of 32
Haas Healthcare Association
Management of Technology
The Bay
![Page 29: Harnessing Nano for Drug Delivery](https://reader033.vdocuments.site/reader033/viewer/2022042320/625d0e9ccb889378fe23acc4/html5/thumbnails/29.jpg)
29 of 32
Initial Incubator (2010-2011)
• Moved into incubator lab at UC Berkeley
2 Co-founders + 1 Employee
![Page 30: Harnessing Nano for Drug Delivery](https://reader033.vdocuments.site/reader033/viewer/2022042320/625d0e9ccb889378fe23acc4/html5/thumbnails/30.jpg)
30 of 32
The East Bay Innovation Center (2011-2013)
• 2 offices!
• 5 lab benches!
• Lots of shared facilities, for better or worse
2 Co-founders + 1 -> 5 Employees = 7
![Page 31: Harnessing Nano for Drug Delivery](https://reader033.vdocuments.site/reader033/viewer/2022042320/625d0e9ccb889378fe23acc4/html5/thumbnails/31.jpg)
31 of 32
Facility Upgrade! (2013-present) 2 Co-founders +
5 -> 10 Employees + 1-2 Interns = 13-14!
< 500 sq ft to > 6000 sq ft
![Page 32: Harnessing Nano for Drug Delivery](https://reader033.vdocuments.site/reader033/viewer/2022042320/625d0e9ccb889378fe23acc4/html5/thumbnails/32.jpg)
32 of 32
Contact: Kayte Fischer [email protected] www.nanoprecisionmedical.com
Thank you for your attention!